Physician profile
Robert E Engstrom
NPI 1689663395
$4,990.50
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,581 · 2020: $375 · 2021: $548 · 2022: $1,126 · 2023: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $1,963.12 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $682.13 | 2020-2023 | Eylea |
| Genentech USA, INC. | $640.64 | 2019-2023 | Lucentis, Vabysmo |
| Allergan, INC. | $476.79 | 2019-2022 | |
| Abbvie INC. | $427.65 | 2022-2023 | |
| Alimera Sciences, INC. | $217.38 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $167.47 | 2022-2023 | Stellaris |
| Novartis Pharmaceuticals Corporation | $120.73 | 2019 | |
| Dutch Ophthalmic, USA | $117.65 | 2019 | |
| Optos, INC. | $41.87 | 2019 | |
| Eyepoint US, INC. | $41.24 | 2020-2021 | |
| Biogen, INC. | $27.95 | 2022 | |
| Apellis Pharmaceuticals, INC. | $25.04 | 2022 | |
| Coherus Oncology, INC. | $22.06 | 2022 | |
| Spark Therapeutics, INC. | $18.78 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Engstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.